Proliposomes for oral delivery: Progress and challenges

Current Pharmaceutical Biotechnology

Volumn 16, Issue 4, 2015, Pages 303-312

  Nekkanti, Vijaykumar ^a   Venkatesan, Natarajan ^b   Betageri, Guru V ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Drug delivery; Lymphatic uptake; Oral bioavailability; Poorly soluble; Proliposomes

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B; BREVISCAPINE; DOXORUBICIN; EXEMESTANE; GLIBENCLAMIDE; IBUPROFEN; INDOMETACIN; ISONIAZID; ISRADIPINE; LIPOSOME; METHOTREXATE; NICOTINE; PHENYLBUTAZONE; PROGESTERONE; PROLIPOSOME; PYRAZINAMIDE; RALOXIFENE; SALCATONIN; SILYMARIN; UNCLASSIFIED DRUG; VINPOCETINE; ZALEPLON; DRUG; LIPID;

ARTICLE; CHEMICAL PROCEDURES; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTENT; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FLOW PROPERTY; FREEZE DRYING; HUMAN; HYDRATION; LIGHT SCATTERING; LIPID DRUG MATRIX METHOD; LIPID FILM DEPOSITION METHOD; MEMBRANE PERMEABILITY; MICROSCOPY; NONHUMAN; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL PARAMETERS; SCANNING ELECTRON MICROSCOP; SPRAY DRYING METHOD; SUPERCRITICAL ANTI SOLVENT METHOD; TRANSEPITHELIAL PERMEABILITY; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; HUMANS; LIPIDS; LIPOSOMES; PHARMACEUTICAL PREPARATIONS;

EID: 84930982293     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201016666150118134256     Document Type: Article

References (69)

1. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070124.pdf, (accessed on Aug 08, 2014 10.21 pm CDT).
2. Williams, H.D.; Trevaskis, N.L.; Charman, S.A.; Shanker, R.M.; Charman, W.N.; Pouton, C.W.; Porter, C.J. Strategies to address low drug solubility in discovery and development. Pharmacol. Rev., 2013, 65(1), 315-499.
3. Merisko-Liversidge, E.M.; Liversidge, G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol., 2008, 36(1), 43-8.
4. Wells, J.I. Pharmaceutical Preformulation: The physicochemical Properties of Drug Substances. 1st ed.; Ellis Horwood Limited: Chichester, 1988; p 21-85;
5. Wells, J. I., Pharmaceutical Preformulation: The physicochemical Properties of Drug Substances. 1st ed.; Ellis Horwood Limited: Chichester, 1988; p 94-100.
6. Florence, A.T.; Attwood, D. Physicochemical Principles of Pharmacy. 2nd ed.; Macmillan Publishers Ltd: London UK, 1981.
7. Lawrence, M.J.; Rees, G.D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev., 2000, 45(1), 89-121.
8. Myrdal, P.B.S.H.Y. Solubilization of Drugs in Aqueous Media. 2nd ed, Encyclopedia of Pharmaceutical Technology. Marcel Dekker, Inc.: New York.: 2002, Vol. 3, pp. 2458-2580.
9. Chaumeil, J.C. Micronization: A method of improving the bioavailability of poorly soluble drugs. Methods Find Exp. Clin. Pharmacol., 1998, 20(3), 211-5.
10. Payne, N.I.; Timmins, P.; Ambrose, C.V.; Ward, M.D.; Ridgway, F. Proliposomes: A novel solution to an old problem. J. Pharm. Sci., 1986, 75(4), 325-329.
11. Kim, K.K.; Pack, D.W. Microspheres for drug delivery. In BioMEMS and Biomedical Nanotechnology, Mauro, F.A.P.L.L.; James, L., Ed. Springer US. 2006, pp, 19-50.
12. Merisko-Liversidge, E. Nanocrystals: Resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. In Particles, JJ, M., Ed. Marcel Dekker: Orlando, 2002.
13. Aburahma, M.H.; Abdelbary, G.A. Novel diphenyl dimethyl bicarboxylate provesicular powders with enhanced hepatocurative activity: Preparation, optimization, in vitro/in vivo evaluation. Int. J. Pharm., 2012, 422(1-2), 139-150.
14. Payne, N.I.; Browning, I.; Hynes, C.A. Characterization of proliposomes. J. Pharm. Sci., 1986, 75(4), 330-333.
15. Bangham, A.D.; Horne, R.W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol., 1964, 8, 660-668.
16. Sessa, G.; Weissmann, G. Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res., 1968, 9(3), 310-318.
17. Ranade, V.V.; Hollinger, M.A. Site specific drug delivery using liposomes as carriers. In Drug delivery systems, Vasant, Ed. CRC Press: Boca Raton, FL, USA. 1996, pp, 3-25p.
18. Cevc, G. Lipid properties as a basis for membrane modeling and rational liposome design. In Liposome technology, Gregoriadis, Ed. CRC: Roca Raton, FL, USA, 1992, Vol. I, pp, 1-36p.
19. Dapergolas, G.; Gregoriadis, G. Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats. Lancet, 1976, 2(7990), 824-827.
20. Zhang, L.; Wang, S.; Zhang, M.; Sun, J. Nanocarriers for oral drug delivery. J. Drug Target, 2013, 21(6), 515-527.
21. O'Hagan, D.T. The intestinal uptake of particles and the implications for drug and antigen delivery. J. Anat., 1996, 189(Pt 3), 477-482.
22. New, R.R.C. Preparation of liposomes. In Liposomes: a practical approach, New, Ed. IRL Press: Oxford; New York, 1990; pp 33-105p.
23. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett., 2013, 8(1), 102.
24. Redondo-Morata, L.; Giannotti, M.I.; Sanz, F. Influence of cholesterol on the phase transition of lipid bilayers: a temperature-controlled force spectroscopy study. Langmuir, 2012, 28(35), 12851-12860.
25. Rong, L.J.B.C.; Sophia, Y.L. Liposomes in solubilization. In Water-Insoluble drug formulation, 2nd ed.; Liu, R., Ed. CRC Press: Boca Raton, FL, USA, 2008, pp, 375-416p.
26. Kulkarni, S.B.; Betageri, G.V.; Singh, M. Factors affecting microencapsulation of drugs in liposomes. J. Microencapsul., 1995, 12(3), 229-246.
27. Betageri, G.V.; Jenkins, S.A.; Parsons, D.L. Liposome drug delivery systems. Technomic Pub.: Lancaster, 1993; p 135 p.
28. Lasic, D.D. Liposomes: From physics to application. Elsevier, 1993, 63-107.
29. Ryan, P.J.; Davis, M.A.; Melchior, D.L. The preparation and characterization of liposomes containing X-ray contrast agents. Biochim. Biophys. Acta, 1983, 756(1), 106-110.
30. Riaz, M. Liposomes preparation methods. Pak. J. Pharm. Sci., 1996, 9(1), 65-77.
31. Katare, O.P.; Vyas, S.P.; Dixit, V.K. Effervescent granule based proliposomes of ibuprofen. J. Microencapsul., 1990, 7(4), 455-462.
32. Kumar, R.; Gupta, R.B.; Betageri, G.V. Formulation, characterization, and in vitro release of glyburide from proliposomal beads. Drug Deliv., 2001, 8(1), 25-27.
33. Potluri, P.; Betageri, G.V. Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Deliv., 2006, 13(3), 227-32.
34. Hiremath, P.S.; Soppimath, K.S.; Betageri, G.V. Proliposomes of exemestane for improved oral delivery: Formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int. J. Pharm., 2009, 380(1-2), 96-104.
35. Xia, F.; Hu, D.; Jin, H.; Zhao, Y.; Liang, J. Preparation of lutein proliposomes by supercritical anti-solvent technique. Food Hydrocolloids, 2012, 26(2), 456-463.
36. Liu, G.; Wang, W.; Wang, H.; Jiang, Y. Preparation of 10-hydroxycamptothecin proliposomes by the supercritical CO2 anti-solvent process. Chem. Eng. J., 2014, 243, 289-296.
37. Rojanarat, W.; Changsan, N.; Tawithong, E.; Pinsuwan, S.; Chan, H.K.; Srichana, T. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int. J. Mol. Sci., 2011, 12(7), 4414-4434.
38. Rojanarat, W.; Nakpheng, T.; Thawithong, E.; Yanyium, N.; Srichana, T. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv., 2012, 19(7), 334-345.
39. Fei, X.; Chen, X.; Liang, G.; Yue-Jian, C.; Hao, W.; Ning, G.; Jia-Bi, Z. Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. J. Drug Target, 2009, 17(5), 408-414.
40. Dipali, S.R.; Kulkarni, S.B.; Betageri, G.V. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods. J. Pharm. Pharmacol., 1996, 48(11), 1112-1115.
41. Xiao, Y.Y.; Song, Y.M.; Chen, Z.P.; Ping, Q.N. Preparation of silymarin proliposomes and its pharmacokinetics in rats. Yao Xue Xue Bao 2005, 40(8), 758-763.
42. Bobbala, S.K.; Veerareddy, P.R. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J. Liposome Res., 2012, 22(4), 285-294.
43. Janga, K.Y.; Jukanti, R.; Velpula, A.; Sunkavalli, S.; Bandari, S.; Kandadi, P.; Veerareddy, P.R. Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. Eur. J. Pharm. Biopharm., 2012, 80(2), 347-357.
44. Velpula, A.; Jukanti, R.; Janga, K.Y.; Sunkavalli, S.; Bandari, S.; Kandadi, P.; Veerareddy, P.R. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. Drug Dev. Ind. Pharm., 2013, 39(12), 1895-1906.
45. Bai, C.; Peng, H.; Xiong, H.; Liu, Y.; Zhao, L.; Xiao, X. Carboxymethylchitosan-coated proliposomes containing coix seed oil: Characterisation, stability and in vitro release evaluation. Food Chem., 2011, 129(4), 1695-1702.
46. Basavaraj, S.; Betageri, G.V. Improved oral delivery of resveratrol using proliposomal formulation: Investigation of various factors contributing to prolonged absorption of unmetabolized resveratrol. Expert Opin. Drug Deliv., 2014, 11(4), 493-503.
47. Balimane, P.V.; Han, Y.H.; Chong, S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J., 2006, 8(1), E1-13.
48. Song, K.H.; Chung, S.J.; Shim, C.K. Preparation and evaluation of proliposomes containing salmon calcitonin. J. Control Release, 2002, 84(1-2), 27-37.
49. Sandhya, K.V.; Devi, G.S.; Mathew, S.T. Liposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 models. Mol. Pharm., 2008, 5(1), 92-97.
50. Ravis, W.R.; Feldman, S. Effect of enzyme-inducing and enzyme-inhibiting agents on drug absorption I: 3-O-methylglucose transport in rats. J. Pharm. Sci., 1978, 67(2), 245-248.
51. Song, K.H.; Chung, S.J.; Shim, C.K. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J. Control Release, 2005, 106(3), 298-308.
52. Chu, C.; Tong, S.S.; Xu, Y.; Wang, L.; Fu, M.; Ge, Y.R.; Yu, J.N.; Xu, X.M. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol. Sin., 2011, 32(7), 973-980.
53. Katare, O.P.; Vyas, S.P.; Dixit, V.K. Proliposomes of indomethacin for oral administration. J. Microencapsul., 1991, 8(1), 1-7.
54. Katare, O.P.; Vyas, S.P.; Dixit, V.K. Enhanced in vivo performance of liposomal indomethacin derived from effervescent granule based proliposomes. J. Microencapsul., 1995, 12(5), 487-493.
55. Katare, O.P.; Vyas, S.P.; Dixit, V.K. Preparation and performance evaluation of plain proliposomal systems for cytoprotection. J. Microencapsul., 1991, 8(3), 295-300.
56. Tantisripreecha, C.; Jaturanpinyo, M.; Panyarachun, B.; Sarisuta, N. Development of delayed-release proliposomes tablets for oral protein drug delivery. Drug Dev. Ind. Pharm., 2012, 38(6), 718-727.
57. Ling, S.S.; Magosso, E.; Khan, N.A.; Yuen, K.H.; Barker, S.A. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev. Ind. Pharm., 2006, 32(3), 335-345.
58. Porter, C.J.; Charman, W.N. Intestinal lymphatic drug transport: An update. Adv. Drug Deliv. Rev., 2001, 50(1-2), 61-80.
59. Chopra, S.; Venkatesan, N.; Betageri, G.V. Formulation of lipid bearing pellets as a delivery system for poorly soluble drugs. Int. J. Pharm., 2013, 446(1-2), 136-144.
60. Dos Santos, N.; Mayer, L.D.; Abraham, S.A.; Gallagher, R.C.; Cox, K.A.; Tardi, P.G.; Bally, M.B. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim. Biophys. Acta, 2002, 1561(2), 188-201.
61. Charrois, G.J.; Allen, T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta, 2004, 1663(1-2), 167-177.
62. Woodley, J.F. Liposomes for oral administration of drugs. Crit. Rev. Ther. Drug Carrier Syst., 1985, 2(1), 1-18.
63. Rogers, J.A.; Anderson, K.E. The potential of liposomes in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 1998, 15(5), 421-480.
64. Payne, N.I.; Cosgrove, R.F.; Green, A.P.; Liu, L. In-vivo studies of amphotericin B liposomes derived from proliposomes: Effect of formulation on toxicity and tissue disposition of the drug in mice. J. Pharm. Pharmacol., 1987, 39(1), 24-28.
65. Park, J.M.; Ahn, B.N.; Yoon, E.J.; Lee, M.G.; Shim, C.K.; Kim, C.K. The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. Biopharm. Drug Dispos., 1994, 15(5), 391-407.
66. Lee, H.J.; Ahn, B.N.; Yoon, E.J.; Paik, W. H.; Shim, C.K.; Lee, M.G. Pharmacokinetics and tissue distribution of adriamycin and adriamycinol after intravenous administration of adriamycin-loaded neutral proliposomes to rats. Int. J. Pharm., 1995, 121(1), 1-10.
67. Xu, H.; He, L.; Nie, S.; Guan, J.; Zhang, X.; Yang, X.; Pan, W. Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J. Control Release, 2009, 140(1), 61-68.
68. Jung, B.H.; Chung, B.C.; Chung, S.J.; Lee, M.H.; Shim, C.K. Prolonged delivery of nicotine in rats via nasal administration of proliposomes. J. Control Release, 2000, 66(1), 73-79.
69. Hwang, B.; Jung, B.; Chung, S.; Lee, M.; Shim, C. In vitro skin permeation of nicotine from proliposomes. J. Control Release, 1997, 49(2-3), 177-184.